Clinical Trial Update: Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19 [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating dexamethasone for severe acute respiratory distress syndrome induced by COVID-19 was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome Adult

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)

Snippet

Sponsor: Centre Chirurgical Marie Lannelongue | Conditions: Respiratory Distress Syndrome, Adult, COVID-19 | Phase 3 | Status: TERMINATED